Increased serum concentration of sphingosine-1-phosphate in juvenile-onset systemic lupus erythematosus

Journal of Clinical Immunology

Volumn 32, Issue 5, 2012, Pages 1019-1025

  Watson, L ^a,b   Tullus, K ^c   Marks, S D ^c   Holt, R C L ^b   Pilkington, C ^c   Beresford, M W ^a,b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ALDER HEY CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

^c NHS Hospital for Children Trust Hospital   (United Kingdom)

Author keywords

Henoch Schonlein Purpura; Lupus; Sphingosine 1 phosphate; UK JSLE

Indexed keywords

ALBUMIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; DOUBLE STRANDED DNA ANTIBODY; IMMUNOSUPPRESSIVE AGENT; SPHINGOSINE 1 PHOSPHATE;

ADOLESCENT; ADULT; ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE URINE LEVEL; DISEASE ACTIVITY; DISEASE CONTROL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; JUVENILE ONSET SYSTEMIC LUPUS ERYTHEMATOSUS; LEUKOCYTE COUNT; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE COUNT; MALE; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; SCHOOL CHILD; STATISTICAL ANALYSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; UNITED KINGDOM; URINALYSIS;

ADOLESCENT; CHILD; COHORT STUDIES; FEMALE; GREAT BRITAIN; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYSOPHOSPHOLIPIDS; MALE; SPHINGOSINE;

EID: 84866735483     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-012-9710-3     Document Type: Article

References (41)

1. Graeler M, Shankar G, Goetzl EJ. Cutting edge: suppression of T cell chemotaxis by sphingosine 1-phosphate. J Immunol. 2002; 169 (8):4084-7.
2. Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature. 2004; 427 (6972):355-60.
3. Kimura A, Ohmori T, Kashiwakura Y, Ohkawa R, Madoiwa S, Mimuro J, et al. Antagonism of sphingosine 1-phosphate receptor-2 enhances migration of neural progenitor cells toward an area of brain. Stroke. 2008; 39(12):3411-7.
4. Yang Y, Uhlig S. The role of sphingolipids in respiratory disease. Ther Adv Respir Dis. 2011; 5(5):325-44.
5. Allende ML, Tuymetova G, Lee BG, Bonifacino E, Wu YP, Proia RL. S1P1 receptor directs the release of immature B cells from bone marrow into blood. J Exp Med. 2010; 207(5):1113-24.
6. Jo SK, Bajwa A, Awad AS, Lynch KR, Okusa MD. Sphingosine-1-phosphate receptors: biology and therapeutic potential in kidney disease. Kidney Int. 2008; 73(11):1220-30.
7. Alvarez SE, Harikumar KB, Hait NC, Allegood J, Strub GM, Kim EY, et al. Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2. Nature. 2010; 465(7301):1084-8.
8. Jacob A, Hack B, Chen P, Quigg RJ, Alexander JJ. C5a/CD88 signaling alters blood-brain barrier integrity in lupus through nuclear factor-kappaB. J Neurochem. 2011; 119(5):1041-51.
9. Zheng L, Sinniah R, Hsu SI. In situ glomerular expression of activated NF-kappaB in human lupus nephritis and other non-proliferative proteinuric glomerulopathy. Virchows Arch. 2006; 448(2):172-83.
10. Zhu LJ, Landolt-Marticorena C, Li T, Yang X, Yu XQ, Gladman DD, et al. Altered expression of TNF-alpha signaling pathway proteins in systemic lupus erythematosus. J Rheumatol. 2010; 37(8):1658-66.
11. Alatab S, Maghbooli Z, Hossein-Nezhad A, Khosrofar M, Mokhtari F. Cytokine profile, Foxp3 and nuclear factor-kB ligand levels in multiple sclerosis subtypes. Minerva Med. 2011; 102(6):461-8.
12. Majumdar I, Mastrandrea LD. Serum sphingolipids and inflammatory mediators in adolescents at risk for metabolic syndrome. Endocrine 2012.
13. Zindler E, Zipp F. Neuronal injury in chronic CNS inflammation. Best Pract Res Clin Anaesthesiol. 2010; 24(4):551-62.
14. Graler MH, Goetzl EJ. The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J. 2004; 18(3):551-3.
15. Killestein J, Rudick RA, Polman CH. Oral treatment for multiple sclerosis. Lancet Neurol. 2011; 10(11):1026-34.
16. Sui M, Zhou J, Xie R, Liu X, Mu S, Jia X, et al. The sphingosine-1- phosphate receptor agonist FTY720 prevents the development of anti-glomerular basement membrane glomerulonephritis. Mol Biol Rep. 2012; 39(1):389-97.
17. Morohoshi K, Osone M, Yoshida K, Nakagawa Y, Hoshikawa S, Ozaki H, et al. The sphingosine 1-phosphate receptor modulator FTY720 prevents iodide-induced autoimmune thyroiditis in non-obese diabetic mice. Autoimmunity. 2011; 44(6):490-5.
18. Chiba K, Kataoka H, Seki N, Shimano K, Koyama M, Fukunari A, et al. Fingolimod (FTY720), sphingosine 1-phosphate receptor modulator, shows superior efficacy as compared with interferon-beta in mouse experimental autoimmune encephalomyelitis. Int Immunopharmacol. 2011; 11(3):366-72.
19. Lai WQ, Irwan AW, Goh HH, Howe HS, Yu DT, Valle-Onate R, et al. Anti-inflammatory effects of sphingosine kinase modulation in inflammatory arthritis. J Immunol. 2008; 181(11):8010-7.
20. Ando S, Amano H, Amano E, Minowa K, Watanabe T, Nakano S, et al. FTY720 exerts a survival advantage through the prevention of end-stage glomerular inflammation in lupus-prone BXSB mice. Biochem Biophys Res Commun. 2010; 394(3):804-10.
21. Watson L, Leone V, Pilkington C, Tullus K, Rangaraj S, McDonagh JE, et al. Juvenile-onset SLE; disease activity, severity and damage - the UK JSLE Cohort Study. Arthritis Rheum 2012.
22. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982; 25 (11):1271-7.
23. Isenberg DA, Rahman A, Allen E, Farewell V, Akil M, Bruce IN, BILAG 2004, et al. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford). 2005; 44(7):902-6.
24. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004; 114(2 Suppl 4th Report):555-76.
25. Norata GD, Pirillo A, Ammirati E, Catapano AL. Emerging role of high density lipoproteins as a player in the immune system. Atherosclerosis. 2012; 220(1):11-21.
26. Bode C, Graler MH. Immune regulation by sphingosine 1-phosphate and its receptors. Arch Immunol Ther Exp (Warsz). 2012; 60(1):3-12.
27. Kataoka H, Sugahara K, Shimano K, Teshima K, Koyama M, Fukunari A, et al. FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Cell Mol Immunol. 2005; 2 (6):439-48.
28. Ishimaru N, Yamada A, Nitta T, Arakaki R, Lipp M, Takahama Y, et al. CCR7 with S1P1 signaling through AP-1 for migration of Foxp3+ regulatory T-cells controls autoimmune exocrinopathy. Am J Pathol. 2012; 180(1):199-208.
29. Okamoto A, Fujio K, Okamura T, Yamamoto K. Regulatory T-cell-associated cytokines in systemic lupus erythematosus. J Biomed Biotechnol. 2011; 2011:463412.
30. Zhu Q, Xia M, Wang Z, Li PL, Li N. A novel lipid natriuretic factor in the renal medulla: sphingosine-1-phosphate. Am J Physiol Renal Physiol. 2011; 301(1):F35-41.
31. Li Q, Wang C, Zhang Q, Tang C, Li N, Li J. The role of sphingosine kinase 1 in patients with severe acute pancreatitis. Ann Surg. 2012; 255(5):954-62.
32. Wenderfer SE, Stepkowski SM, Braun MC. Increased survival and reduced renal injury in MRL/lpr mice treated with a novel sphingosine-1-phosphate receptor agonist. Kidney Int. 2008; 74 (10):1319-26.
33. Kulakowska A, Zendzian-Piotrowska M, Baranowski M, Kononczuk T, Drozdowski W, Gorski J, et al. Intrathecal increase of sphingosine 1-phosphate at early stage multiple sclerosis. Neurosci Lett. 2010; 477 (3):149-52.
34. Marks SD, Shah V, Pilkington C, Tullus K. Urinary monocyte chemoattractant protein-1 correlates with disease activity in lupus nephritis. Pediatr Nephrol. 2010; 25(11):2283-8.
35. Watson L, Midgley A, Pilkington C, Tullus K, Marks SD, Holt RC, et al. Urinary monocyte chemoattractant protein 1 and alpha 1 acid glycoprotein as biomarkers of renal disease activity in juvenile-onset systemic lupus erythematosus. Lupus 2011.
36. Lin CI, Chen CN, Chen JH, Lee H. Lysophospholipids increase IL-8 and MCP-1 expressions in human umbilical cord vein endothelial cells through an IL-1-dependent mechanism. J Cell Biochem. 2006; 99(4):1216-32.
37. Lin CI, Chen CN, Lin PW, Lee H. Sphingosine 1-phosphate regulates inflammation-related genes in human endothelial cells through S1P1 and S1P3. Biochem Biophys Res Commun. 2007; 355(4):895-901.
38. Poti F, Bot M, Costa S, Bergonzini V, Maines L, Varga G, et al. Sphingosine kinase inhibition exerts both pro-and anti-atherogenic effects in low-density lipoprotein receptor-deficient (LDL-R-/-) mice. Thromb Haemost. 2012; 107(3).
39. Sola A, Weigert A, Jung M, Vinuesa E, Brecht K, Weis N, et al. Sphingosine-1-phosphate signalling induces the production of Lcn-2 by macrophages to promote kidney regeneration. J Pathol. 2011; 225(4):597-608.
40. Hinze CH, Suzuki M, Klein-Gitelman M, Passo MH, Olson J, Singer NG, et al. Neutrophil gelatinase-associated lipocalin is a predictor of the course of global and renal childhood-onset systemic lupus eryth-ematosus disease activity. Arthritis Rheum. 2009; 60(9):2772-81.
41. Rubinstein T, Pitashny M, Levine B, Schwartz N, Schwartzman J, Weinstein E, et al. Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis. Rheumatology (Oxford). 2010; 49(5):960-71.